Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, Wong DJL, Atefi M, Shirazi R, Wang X, Braas D, Grasso CS, Palaskas N, Ribas A, Graeber TG. Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell. 2018 May 14;33(5):890-904.e5.
Chung SS, Wu Y, Okobi Q, Adekoya D, Atefi M, Clarke O, Dutta P, Vadgama JV. Proinflammatory Cytokines IL-6 and TNF-α Increased Telomerase Activity through NF-κB/STAT1/STAT3 Activation, and Withaferin A Inhibited the Signaling in Colorectal Cancer Cells. Mediators Inflamm. 2017;2017:5958429.
Wu Y, Yu X, Yi X, Wu K, Dwabe S, Atefi M, Elshimali Y, Kemp KT 2nd, Bhat K, Haro J, Sarkissyan M, Vadgama JV. Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res. 2017 Mar 15;77(6):1383-1394.
Wu Y, Dong Y, Atefi M, Liu Y, Elshimali Y, Vadgama JV. Lactate, a Neglected Factor for Diabetes and Cancer Interaction. Mediators Inflamm. 2016;2016:6456018.
Atefi M, Titz B, Avramis E, Ng C, Wong D, Lassen A, Cerniglia M, Escuin-Ordinas H, Foulad D, Comin-Anduix B, Graeber TG, Ribas A. Combination of Pan-RAF and MEK inhibitors in NRAS mutant melanoma. Mol Cancer. 2015 Feb 3;14(1):27.
Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer. 2014 Aug 20;13:194.
Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A. Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma. Clin Cancer Res. 2014 Jul 1;20(13):3446-57. doi: 10.1158/1078-0432.CCR-13-2797. Epub 2014 May 8. (chosen as one of the highlighted articles of the July1st issue)
Wong DJ, Rao A, Avramis E, Matsunaga DR, Komatsubara KM, Atefi MS, Escuin-Ordinas H, Chodon T, Koya RC, Ribas A, Comin-Anduix B. Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res. 2014 May;2(5):459-68.
Lassen A, Atefi M, Robert L, Wong DJ, Cerniglia M, Comin-Anduix B, Ribas A. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol Cancer. 2014 Apr 16;13(1):83.
Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR, Yashar S, Comin-Anduix B, Avramis E, Cochran AJ, Marais R, Lo RS, Graeber TG, Herschman HR, Ribas A. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Mol Oncol. 2013 Dec 1. pii: S1574-7891(13)00163-4.
Helena Escuin-Ordinas, Mark W Elliott, Mohammad Atefi, Michelle Lee, Charles Ng, Liu Wei, Begoña Comin-Anduix, Encarnacion Montecino-Rodriguez, Earl Avramis, Caius Radu, Leslie L Sharp and Antoni Ribas. PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody. Journal for ImmunoTherapy of Cancer 2013, 1:14.
Mohammad S. Atefi, Charles P. Ng, Deborah J. Wong, Lidia Robert, Helena Escuin-Ordinas, Amanda Lassen, David Foulad, Begonya Comin-Anduix, Ahmad A. Samatar, and Antoni Ribas. Melanomas with rare BRAF mutations and their responses to MAPK pathway blocking drugs. Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1. AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. Abstract 915.
Deborah J. Wong, Lidia Robert, Mohammad S. Atefi, David Foulad, Earl V. Avramis, Begonya Comin-Anduix, Ahmed A. Samatar, and Antoni Ribas. High antitumor activity of the ERK inhibitor SCH722984 against BRAF-mutant, NRAS-mutant and wild-type melanoma cell lines. Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1. AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. Abstract 917
Frédéric D. Birkhäuser, Richard C. Koya, Caleb Neufeld, Xuyang Lu, Ewa D. Micewicz, Thinle Chodon, Mohammad Atefi, Nils Kroeger, Edward N. Rampersaud, Gadisetti VR Chandramouli, Gang Li, Jonathan W. Said, Antoni Ribas, William H. McBride, Fairooz F. Kabbinavar, Allan J. Pantuck, Arie S. Belldegrun, and Joseph Riss. Dendritic Cell-Based Immunotherapy in Prevention and Treatment of Renal Cell Carcinoma: Efficacy, Safety, and Activity of Ad-GMCAIX in Immunocompetent Mouse Models. J. of Immunotherapy 2013 Feb;36(2):102-11..
M. S. Atefi, D. Wong, C. Ng, L. Robert, E. Avramis, H. EsCuin Ordinas, B. Comin-Anduix, A. Ribas. Combination of Pan-RAF and MEK inhibitors to treat NRAS mutant melanoma cell lines. Pigment Cell Melanoma Res. 25; 836–903. Abstract and poster presentation. Awarded of the best poster at Society for Melanoma Research 2012 Congress.
Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W.BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2012 Sep;2(9):791-7. Epub 2012 Jul 13.
*von Euw E, *Atefi M, Attar N, Chu C, Zachariah S, Burgess BL, Mok S, Ng C, Wong DJ, Chmielowski B, Lichter DI, Koya RC, McCannel TA, Izmailova E, Ribas A. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer. 2012 Apr 19;11:22. * Equal contribution.
Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Nov 23;480(7377):387-90.
Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011;6(12):e28973.
Helena Escuin-Ordinas, Mohammad Atefi, Charles Ng, Leslie Sharp, Antoni Ribas. PET imaging of antitumor responses with anti-4-1BB (anti-CD137). Cancer Research: April 15, 2012; Volume 72, Issue 8, Supplement 1. Abstract and poster presentation at American Association of Cancer Research (AACR), 103st annual meeting, 2012.
Antoni Ribas, Thinle Chodon, Begonya Comin-Anduix, Jonas Sondergaard, Stephen Mok, Charles Ng, Helena Escuin-Ordinas, Mohammad Atefi, Bartosz Chmielowski, Johannes Czernin, Owen N. Witte, Caius G. Radu, and Richard C. Koya. Novel imaging approaches for immunotherapy and targeted therapy of melanoma in animal models and humans. Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1. Oral presentation at American Association of Cancer Research (AACR), 102st annual meeting, 2011.
Mohammad S. Atefi, Cristina Zheng, Zahra Atefi, Dennis J. Slamon. Effect of estrogen receptor antagonistic drugs on expression and regulation of fatty acid synthase (FAS) in ER+ breast cancer cell lines. Cancer Research: April 15, 2010; Volume 70, Issue 8, Supplement 1. Abstract and poster presentation at American Association of Cancer Research (AACR), 101st annual meeting, 2010.
Richard S Finn, Judy Dering, Dylan Conklin, Ondrej Kalous, David J Cohen, Amrita J Desai, Charles Ginther, Mohammad Atefi, Isan Chen, Camilla Fowst, Gerret Los, Dennis J Slamon. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research 2009, 11:R77.
Mohammad S. Atefi, Neil A. O’Brien, Yasser S. Attiga, Margaret M. Kozak, Charles L. Ginther, Dennis J. Slamon. Enhanced expression of AREG and FGFR2 and increased activity of peptide growth factor signaling pathways induce resistance to fulvestrant and tamoxifen. American Association of Cancer Research (AACR), 100th annual meeting, 2009. Poster presentation, Abstract 4725.
Neil A. O’Brien, Brigid C. Browne, Lucy Chow, Charles Ginther, Jane Arboleda, Mohammad Atefi, Michael J. Duffy, John Crown, Norma O’Donovan and Dennis J. Slamon Activated PI3K and RTK signaling and response/resistance to HER2 targeted therapy. American Association of Cancer Research (AACR), 100th annual meeting, 2009. Poster presentation, Abstract 765.
Mohammad S. Atefi, Dennis J Slamon. Fulvestrant provides further growth inhibitory effects in ER+ cell lines in which tamoxifen induces PR expression and in cell lines with average activities of growth factor signaling. American Association of Cancer Research (AACR), 99th annual meeting, 2008. Poster presentation, Abstract 1468.
Virginia Hill, Michael Schaffer, Mohammad Atefi, Oscar Chao, Paul Matsui. Studies of four extraction methods for recovery of opiates from hair. Society of Forensic Toxicologists (SOFT) Annual Conference, Durham, North Carolina, October, 2007. Poster presentation.